BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19714305)

  • 21. Dose response in prostate cancer with 8-12 years' follow-up.
    Hanks GE; Hanlon AL; Epstein B; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):427-35. PubMed ID: 12243818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions.
    Hanks GE; Hanlon AL; Schultheiss TE; Pinover WH; Movsas B; Epstein BE; Hunt MA
    Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):501-10. PubMed ID: 9635695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis.
    Livsey JE; Cowan RA; Wylie JP; Swindell R; Read G; Khoo VS; Logue JP
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1254-9. PubMed ID: 14630259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.
    Michalski JM; Bae K; Roach M; Markoe AM; Sandler HM; Ryu J; Parliament MB; Straube W; Valicenti RK; Cox JD
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):14-22. PubMed ID: 19577865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
    Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R
    Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects.
    Dearnaley DP; Hall E; Lawrence D; Huddart RA; Eeles R; Nutting CM; Gadd J; Warrington A; Bidmead M; Horwich A
    Br J Cancer; 2005 Feb; 92(3):488-98. PubMed ID: 15685244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer: preliminary results of a phase I/II study.
    Kitamura K; Shirato H; Shinohara N; Harabayashi T; Onimaru R; Fujita K; Shimizu S; Nonomura K; Koyanagi T; Miyasaka K
    Cancer J; 2003; 9(4):268-76. PubMed ID: 12967137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose selection for prostate cancer patients based on dose comparison and dose response studies.
    Hanks GE; Hanlon AL; Pinover WH; Horwitz EM; Price RA; Schultheiss T
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):823-32. PubMed ID: 10705002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.
    Patel N; Faria S; Cury F; David M; Duclos M; Shenouda G; Ruo R; Souhami L
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):534-9. PubMed ID: 23597418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
    Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M
    Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Image guided dose escalated prostate radiotherapy: still room to improve.
    Martin JM; Bayley A; Bristow R; Chung P; Gospodarowicz M; Menard C; Milosevic M; Rosewall T; Warde PR; Catton CN
    Radiat Oncol; 2009 Nov; 4():50. PubMed ID: 19887007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The treatment of nonpalpable PSA-detected adenocarcinoma of the prostate with 3-dimensional conformal radiation therapy.
    Horwitz EM; Hanlon AL; Pinover WH; Hanks GE
    Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):519-23. PubMed ID: 9635697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxicity report of once weekly radiation therapy for low-risk prostate adenocarcinoma: preliminary results of a phase I/II trial.
    Menkarios C; Vigneault É; Brochet N; Nguyen DH; Bahary JP; Jolicoeur M; Beauchemin MC; Villeneuve H; Van Nguyen T; Fortin B; Lambert C
    Radiat Oncol; 2011 Sep; 6():112. PubMed ID: 21906281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.
    Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K
    Tumori; 2014; 100(3):265-71. PubMed ID: 25076236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensity modulated radiotherapy (IMRT) or conformational radiotherapy (3D-CRT) with conventional fractionation for prostate cancer: Is there any clinical difference?
    Viani G; Hamamura AC; Faustino AC
    Int Braz J Urol; 2019; 45(6):1105-1112. PubMed ID: 31808397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rotational 3D-conformal radiation therapy (conformation therapy) combined with hormone therapy for the treatment of stage B2/C prostate cancer in Japanese men.
    Karasawa K; Kaizu T; Niibe Y; Igaki H; Shinohara M; Tanaka Y; Matsuda T
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):208-12. PubMed ID: 12694840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer.
    Vora SA; Wong WW; Schild SE; Ezzell GA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1053-8. PubMed ID: 17398023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.